![](/img/cover-not-exists.png)
PCN245 GRADE 3/4 ADVERSE EVENT (AE) COSTS OF NIVOLUMAB VERSUS DABRAFENIB + TRAMETINIB AS ADJUVANT TREATMENT IN PATIENTS WITH STAGE III BRAF-MUTATED CUTANEOUS MELANOMA IN PORTUGAL
Alves, D., Amadi, A., Moshyk, A., Betts, K., Du, E.X.Volume:
22
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.09.440
Date:
November, 2019
File:
PDF, 382 KB
2019